Richard Summa, MD
Pulmonary Disease · Bridgeton, MONPI 1558334227
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $2,174 of the $2,880 with a category attached, or 75.5%. 3 manufacturers reported payments, led by Pfizer at 58.4% of the total. Reporting peaked in 2019 at $2,810 and has fallen 98.7% since, to $37 in 2025.
Across 15 payments — averaging $191.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$2K
- Eli Lilly$1K
- Apria Healthcare LLC$13
Across 14 payments — averaging $13,150 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$163K
- Pfizer$21K
What the payments were for
- Travel & lodging$2,17475%
- Food & beverage$70625%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 8 | $1,682 |
| Eli Lilly | 6 | $1,185 |
| Apria Healthcare LLC | 1 | $13 |
How this compares
$2,880 in reported general payments places this provider in the 55th percentile of 295 pulmonary disease providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 390 | $397,340 |
| Dupixent PenDupilumab | 48 | $189,025 |
| Breo ElliptaFluticasone/Vilanterol | 131 | $86,781 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 97 | $71,303 |
| SymbicortBudesonide/Formoterol Fumarate | 94 | $40,747 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 54 | $38,147 |
| Spiriva HandihalerTiotropium Bromide | 35 | $35,578 |
| Incruse ElliptaUmeclidinium Bromide | 53 | $35,441 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 113 | $30,901 |
| Arnuity ElliptaFluticasone Furoate | 68 | $30,868 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 25 | $25,941 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 33 | $24,203 |
| Spiriva RespimatTiotropium Bromide | 25 | $20,386 |
| ArexvyRsvpref3 Antigen/As01e/Pf | 72 | $18,316 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 95 | $16,157 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerLyrica | $1,682 | $4,82411 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 295 pulmonary disease providers in Missouri.
Other pulmonary disease in Bridgeton
- Humam FarahHannibal$840K
- Derek ByersSaint Louis$835K
- Alexander ChenSaint Louis$679K
- Joseph OjileSaint Louis$538K
- Munaf SiyamwalaIndependence$413K
- Edward CharbekSaint Louis$372K
- Adeel KhanWashington$316K
- Marin KollefSaint Louis$264K
- Praveen ChennaSaint Louis$255K
- Bobby ShahChesterfield$241K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.